Finally, the detected CpG-SNPs could be used to better predict age of onset in C9orf72 asymptomatic carriers in preventive clinical trials (e.g. based on the Genetic Frontotemporal dementia Initiative study) (Rohrer et al., 2015), for designing conditional and/or modifiers studies in the sporadic FTLD spectrum, such as based on IFGC related projects (https://ifgcsite.wordpress.com/) and for genetic counselling. This evidence concerns the gene C9orf72 and dementia.